ABOUT COHERUS

BOARD OF DIRECTORS

OUR BOARD OF DIRECTORS LEVERAGES THE TALENTS OF HIGHLY REGARDED LEADERS IN LIFE SCIENCES, FINANCE AND CONSULTING.

  • DENNIS M. LANFEAR

    PRESIDENT, CEO & CHAIRMAN

    • DENNIS M.
      LANFEAR

      PRESIDENT, CEO & CHAIRMAN

      Dennis Lanfear is a biotechnology pioneer and leader with a track record for entrepreneurial vision and achievement. He founded Coherus Biosciences in 2010, assuming the roles of President, CEO and Chairman, and quickly turned the company from a startup into the industry’s leading “pure play” in biosimilar drugs. Having recruited some of biotech’s most accomplished drug developers, Coherus has built a late stage pipeline of biosimilar treatments for inflammatory diseases and cancer. The team Mr. Lanfear put together is now delivering on its vision of improved access to high quality, life-changing medicines. Coherus is backed by more than $400M in capital raised from the public and private markets. This includes over $110M in net proceeds from an April 2015 follow-on public offering, over $80M in net proceeds from a November 2014 IPO, and over $220M in private financing. Collaborations with Daiichi Sankyo and Baxter International further strengthen the company’s global drug development agenda.

      Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen, where he served as a Vice President with broad operational, product development and marketing responsibility. He spend 10 of those years running Amgen’s renowned Process Development Department, where he was tasked with integrating more than 2,500 operations and staff worldwide. Mr. Lanfear spearheaded multiple development programs for growth factors, somatotropins and neurotrophins, taking these products from preclinical to Phase 3. He reviewed and wrote sections of more than 20 INDs and several BLAs, and he had direct budgetary responsibility for the $135 million development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 Mr. Lanfear was named Amgen’s Vice President, Market Development. In this role, he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.

      Prior to joining Amgen, Mr. Lanfear held positions at Baxter International and was also the founder and CEO of Saronyx, Inc., a drug development software services company. In 2005, he founded InteKrin Therapeutics, serving as President, CEO, and Chairman in 2010. He is an investor in and former director of Anthera Pharmaceuticals, and a former director of Insmed Therapeutics. Mr. Lanfear holds biochemistry and chemical engineering degrees from Michigan State University and an MBA from the Anderson School at UCLA.

  • MATS WAHLSTRÖM

    CEO & CHAIRMAN, KMG CAPITAL PARTNERS, LLC

    • MATS
      WAHLSTRÖM

      CEO & CHAIRMAN, KMG CAPITAL PARTNERS, LLC

      Mats Wahlström, Lead Director, has served as a member of our Board of Directors since January 2012.

      Mr. Wahlström serves as the Chief Executive Officer and Chairman of KMG Capital Partners, LLC since April 2012, Chairman of PCI | HealthDev since August 2010, and Chairman of Caduceus Medical Holdings, LLC since August 2010. He has served on the boards of directors of Getinge AB since March 2012 and Alteco Medical AB since October 2012. He served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, and as a director of Zynex Inc., an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGAA. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, Mr. Wahlström held various positions at Gambro AB in Sweden, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.

      Mr. Wahlström has a B.S. degree in Economics and Business Administration from University of Lund, Sweden.

      We believe Mr. Wahlström is qualified to serve on our Board of Directors because of his extensive management and director experience in the life sciences and healthcare sectors.

  • JAMES HEALY, M.D., PH.D.

    GENERAL PARTNER, SOFINNOVA VENTURES

    • JAMES
      HEALY, M.D., PH.D.

      GENERAL PARTNER, SOFINNOVA VENTURES

      James I. Healy, M.D., Ph.D. has been a member of our Board of Directors since February 2014. Dr.

      Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Amarin Corporation plc, Ascendis Pharma, Auris Medical, Natera, and several private companies. Previously, he served as a board member of InterMune, Inc., Hyperion Therapeutics, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies.

      Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford University School of Medicine, a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

      We believe Dr. Healy is qualified to serve on our Board of Directors due to his extensive experience investing and working within the pharmaceuticals industry, as well as his extensive service on the boards of directors of several other life sciences companies.

  • V. BRYAN LAWLIS, PH.D.

    INDEPENDENT CONSULTANT

    • V. BRYAN
      LAWLIS, PH.D.

      INDEPENDENT CONSULTANT

      FORMERLY

      Genentech

      V. Bryan Lawlis, Ph.D. has served on our Board of Directors since May 2014 and prior to that he served as the chairman of our Scientic Advisory Board from November 2012, until he joined the board in May 2014.

      Since August 2011, he has served as the President and Chief Executive Officer of ltero Biopharmaceuticals, LLC, a privately held limited liability holding company, which has held the assets of ltero Biopharmaceuticals, Inc., or Itero Biopharmaceuticals, since August 2011. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, from 2006, until it discontinued operations in August 2011. Prior to that, he served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004, and served on its board of directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President from June 2003 to August 2004, and as its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing company, served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis has served on the boards of directors of two privately held companies, Sutro Biopharmaceuticals, Inc. since 2003 and Reform Biologics, LL since February 2014. He has also served on the boards of directors at BioMarin Pharmaceutical Inc., a public biopharmaceutical company since June 2007, and Geron Corporation, a public biopharmaceutical company, since March 2012.

      Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.

      We believe Dr. Lawlis is qualified to serve on our Board of Directors due to his longtime involvement in the biotechnology industry, and extensive service as a director or officer of other life sciences companies.

  • CHRISTOS RICHARDS

    PARTNER, CATALYST ADVISORS L.P.

    • CHRISTOS
      RICHARDS

      PARTNER, CATALYST ADVISORS L.P.

      Christos Richards has served as a member of our Board of Directors since March 2011.

      Christos Richards, is a partner based in Catalyst Advisors’ Los Angeles office. Before joining Catalyst Advisors, Christos spent 15 years as the chief executive officer of a boutique healthcare executive search firm. While leading a team of nearly 20 consultants across five offices, Christos worked with clients in North America, Europe and Asia. His career spans over 30 years of experience in executive search and human resource consulting, preceded by 5 years of general management in Switzerland.

      Mr. Richards was educated in Switzerland and is fluent in German and Swiss German.

      Mr. Richards brings to the board, experience in the recruitment of numerous executive level professionals, including a diverse range of C-level and VP-level executives. We believe Mr. Richards is qualified to serve on our Board of Directors based on his extensive senior management experience and expertise.

  • ALI J. SATVAT

    MEMBER, KOHLBERG KRAVIS ROBERTS & CO. L.P. (KKR)

    • ALI J.
      SATVAT

      MEMBER, KOHLBERG KRAVIS ROBERTS & CO. L.P. (KKR)

      Ali J. Satvat has served as a member of our Board of Directors since May 2014.

      Mr. Satvat is a Member of KKR and a senior leader of the Health Care industry team within KKR’s Americas Private Equity platform since January 2012. He has also served as a member of the board of directors of several organizations, including Cohera Medical, Inc. since October 2015, Arbor Pharmaceuticals, Inc. since January 2015 and PRA Health Sciences, Inc. since September 2013. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012, served as a director of Chiron Holdings (Kinetic Concepts, Inc. and LifeCell Corporation) and TZ Holdings (The TriZetto Group, Inc.) and was actively involved with many of the firm’s successful growth investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group, where he was involved in a broad range of transactions.

      Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania.

      Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association. We believe Mr. Satvat is qualified to serve on our Board of Directors based on his extensive investment experience in the health care industry.

  • MARY SZELA

    CEO, AEGERION PHARMACEUTICALS

    • MARY
      SZELA

      CEO, AEGERION PHARMACEUTICALS

      Mary T. Szela has served as a member of our Board of Directors since July 2014.

      Ms. Szela is the Chief Executive Officer of Aegerion Pharmaceuticals. Prior to joining Aegerion in January 2016, Ms. Szela was Chief Executive Officer of Melinta Therapeutics, where she managed the company’s rebranding effort and led the reprioritization and expansion of the advanced-stage product pipeline. Previously, Ms. Szela joined Abbott Laboratories in 1987 and has held several leadership positions, including Senior Vice President of Global Strategic Marketing from January 2010 to May 2012 and Senior Vice President of U.S. Pharmaceuticals from September 2008 to December 2009. Prior to Abbott, Ms. Szela worked for the University of Illinois Hospital. She has served on the board of directors of Suneva Medical, Inc. since July 2012.

      Ms. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois.

      We believe Ms. Szela is qualified to serve on our Board of Directors because of her extensive management experience and expertise in pharmaceutical company operations.

  • AUGUST TROENDLE, M.D.

    PRESIDENT, CEO & CHAIRMAN, MEDPACE, INC.

    • AUGUST
      TROENDLE, M.D.

      PRESIDENT, CEO & CHAIRMAN, MEDPACE, INC.

      August J. Troendle, M.D. has served as a member of our Board of Directors since March 2011.

      Dr. Troendle has been the Chief Executive Officer, President and Chairman of Medpace, Inc., a clinical research organization, since its inception in 1992. Dr. Troendle previously worked for Sandoz (Novartis) where he was responsible for the clinical development of lipid altering agents. His experience as Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA gives him insight into the regulatory environment for development of drugs in the metabolic and cardiovascular fields. He also formerly served on the board of directors of Xenon Pharmaceuticals Inc. from 2009 to 2010. Dr. Troendle received his M.D. from the University of Maryland, School of Medicine.

      We believe Dr. Troendle is qualified to serve on our Board of Directors based on his experience in clinical research and expertise in regulatory oversight.

leadership

view now

scientific advisory board

view now